Lascufloxacin
As of the edition of 20 October 2026, Lascufloxacin is a small molecule: marketed, first approved in 2019 (JP).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2019
- Kind
- Small molecule
- Brand name
- Lasvic
- First approved
- 22 August 2019 (JP)
- Approvals on record
- 3 in 1 region
- Holder of the most recent approval
- Kyorin Pharmaceutical
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Kyorin Pharmaceutical | Originator | 2019 to now |